Georgia Angelopoulou, Dimitrios Kasselimis, George Makrydakis, Maria Varkanitsa, Petros Roussos, Dionysis Goutsos, Ioannis Evdokimidis, Constantin Potagas, Neuropsychologia, Available online 7 April 2018, ISSN 0028-3932, doi:10.1016/j.neuropsychologia.2018.04.006.
Several studies have demonstrated that pausing may be affected by neurological conditions. Individuals with amyotrophic lateral sclerosis and Friedreich’s Ataxia have been shown to produce longer pauses in conversational speech compared to controls. These studies clearly show prominent differences in pausing between healthy participants and pathological populations. These studies have also demonstrated how pausing measures may be used as diagnostic markers and/or as markers of cognitive changes over time. Taken together, these findings suggest that pauses could be an integral aspect of cognitive assessment in clinical practice and research.
Sunday, April 8, 2018
Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia
Theresa Zesiewicz MD, FAAN, Frederic Heerinckx MPharm, Robert De Jager MD, FACP, Omid Omidvar MD, Marcus Kilpatrick PhD, Jessica Shaw MPH, Mikhail S. Shchepinov PhD, Movement Disorders : Official Journal of the Movement Disorder Society, First published: 6 April 2018 doi:10.1002/mds.27353
RT001 was found to be safe and tolerable over 28 days, and improved peak workload. Further research into the effect of RT001 in Friedreich's ataxia is warranted.
RT001 was found to be safe and tolerable over 28 days, and improved peak workload. Further research into the effect of RT001 in Friedreich's ataxia is warranted.
Strong correlations among four measures of disease progression in Friedreich's ataxia
Harry J. Saal PhD, Frederic Heerinckx, Rezi Zawadzki DrPH, Omid Omidvar MD, Marcus Kilpatrick PhD, Theresa Zesiewicz MD, Movement Disorders : Official Journal of the Movement Disorder Society [06 Apr 2018] Letter DOI: 10.1002/mds.27351
Using the data from a double-blind, placebo-controlled trial in 19 FRDA patients testing RT001 a linoleic acid derivative, baseline FARS-Neuro scores were compared with T25FW and CPET to measure peak workload/kg and peak oxygen consumption.
Using the data from a double-blind, placebo-controlled trial in 19 FRDA patients testing RT001 a linoleic acid derivative, baseline FARS-Neuro scores were compared with T25FW and CPET to measure peak workload/kg and peak oxygen consumption.
Subscribe to:
Posts (Atom)
